Long-term safety and tolerability of lurasidone in schizophrenia: A 12-month, double-blind, active-controlled study

International Clinical Psychopharmacology

Volumn 27, Issue 3, 2012, Pages 165-176

  Citrome, Leslie ^a   Cucchiaro, Josephine ^b   Sarma, Kaushik ^b   Phillips, Debra ^b   Silva, Robert ^b   Tsuchiya, Satoru ^b   Loebel, Antony ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

double blind; lurasidone; risperidone; safety; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LURASIDONE; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADULT; AKATHISIA; ANXIETY; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; VITAL SIGN; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; AMBULATORY CARE; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CROATIA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOINDOLES; ISRAEL; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOUTH AFRICA; SOUTH AMERICA; THAILAND; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84859268864     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32835281ef     Document Type: Article

References (10)

1. Citrome L (2008). Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand 117:412-419. (Pubitemid 351678479)
2. Citrome L (2009). Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 4:229-237.
3. Citrome L (2011). Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 65:189-210.
4. Fitzmaurice GM, Laird NM, Ware JH (2004). Applied longitudinal analysis. 1st ed. Hoboken, NJ: Wiley.
5. Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A (2011). Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 125:161-168.
6. Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, et al. (2011). Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and olanzapine-controlled study. Am J Psychiatry 168:957-967.
7. Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, et al. (2009). Lurasidone in the treatment of acute schizophrenia: a double-blind, placebocontrolled trial. J Clin Psychiatry 70:829-836.
8. Rosenheck RA, Davis VG, Davis SM, Stroup S, McEvoy J, Swartz M, et al. (2009). Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. Schizophr Res 113:12-18.
9. Shayegan DK, Stahl SM (2004). Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr 10 (Suppl 11):6-14. (Pubitemid 39473434)
10. Volavka J, Citrome L (2009). Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision making. Expert Opin Pharmacother 10:1917-1928.